Trials / Completed
CompletedNCT02205606
Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia
A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 412 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HGP0816 5mg | P.O. |
| DRUG | HGP0816 10mg | P.O. |
| DRUG | HGP0816 20mg | P.O. |
| DRUG | HCP1306 5/10mg | P.O. |
| DRUG | HCP1306 10/10mg | P.O. |
| DRUG | HCP1306 20/10mg | P.O. |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-02-01
- Completion
- 2015-04-01
- First posted
- 2014-07-31
- Last updated
- 2015-09-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02205606. Inclusion in this directory is not an endorsement.